抗肿瘤中药新型药物传递系统的研究(二)——活血化瘀类中药  

Progress in Novel Drug Delivery Systems of Anti-tumor Traditional Chinese Medicine——Blood-activating and Stasis-resolving Chinese medicine

作　　者：申东艳[1] 陈美婉[1] 王胜鹏[1] 李鹏[1] 王一涛[1] 

机构地区：[1]澳门大学中药质量研究国家重点实验室/澳门大学中华医药研究院,澳门999078

出　　处：《世界科学技术-中医药现代化》2013年第1期34-39,共6页Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology

基　　金：澳门特别行政区科学技术发展基金项目(077/2011/A3):基于网络药理和分子药剂的创新中药关键技术研究;负责人:王一涛;澳门大学研究基金项目(MYRG208(Y2-L4)-ICMS11-WYT):基于系统药理学的中药药剂学平台;负责人:王一涛

摘　　要：活血化瘀类抗肿瘤中药如莪术、姜黄和延胡索等通过改善血液高凝状态和恶性肿瘤的内环境,发挥其抗肿瘤作用,尤其在抗肿瘤转移方面具有优势,但其有效成分(挥发油等)多存在稳定性差、吸收困难和生物利用度低等缺陷,严重影响了该类中药的临床治疗效果。在中医药理论的指导下,新型药物传递系统已使活血化瘀类抗肿瘤中药得到广泛的研究和开发,进一步拓展了活血化瘀类抗肿瘤中药的临床使用。本文针对活血化瘀类抗肿瘤中药的新型药物传递系统,以及对常用的莪术、姜黄、虎杖等3种活血化瘀类抗肿瘤中药的新型制剂进行综述,旨在为该类抗肿瘤中药新剂型的研发提供理论和现实参考。Blood-activating and stasis-resolving Chinese medicine, such as Rhizoma Curcumae, Rhizoma Curcumae Longae and Rhizoma Corydalis, can work as anti-tumor medicines especially in the area of anti-metastatic by changing the blood hypercoagulable state and improving internal environment of tumors. However, lots of active ingredients from this kind of medicine including volatile oil have the disadvantage of poor stability and absorption, and low bioavailability which have weakened the clinical application. In recent years, under the guidance of Chinese medicine theory and advanced technology of modem pharmaceutics based on new pharmaceutical excipients and preparation process, novel drug delivery systems, for example, liposome, microsphere, microcapsule, nanoparticle, and solid dispersion, have already been used in the research and development of this kind of Chinese medicines. This paper reviewed the novel drug delivery systems of blood-activating and stasis-resolving Chinese medicine and focused on Rhizoma Curcumae, Rhizoma Curcumae Longae, and Rhizoma Polygoni Cuspidati. We hope to provide theoretical and practical reference for the research and development of new formulations in antitumor Chinese medicine.

关 键 词：抗肿瘤中药 新型药物传递系统 活血化瘀药 

分 类 号：R711.71[医药卫生—妇产科学]